firstly, the newly rented space in Marlboro MA, present headquarters is in Westboro Ma.
Secondly, I am very curious how you would know whether or not either location has "nothing to do with sales in Europe?
Go to company website, investors, sign up..................good luck All
Wild, I might suggest that if oculus was confidant in their drug as a reducer of scarring they would surely have developed it as such. I am fairly certain that some topicalo creams have skin tightening effects that may possibly show a slight improvement in dimensions of a scar, and temporary at best.
Please keep in mind that rxi-109 is designed as a pre surgical application to reduce scarring in planned surguries.
Oculus topical treatment is not approved as an anti scarring agent and up to now scar reduction remains an unmet need...GLTA
Quite simply. oculus' drug is for the relief of the discomfort of scarring. It was neither tested for or approved by FDA as a treatment for scar reduction. It is a topical cream for relief....................good luck All
By Everdeen Mason
Oculus Innovative Sciences Inc. (OCLS) said it received approval from the U.S. Food & Drug Administration for its scar medication, Microcyn Scar Management Hydrogel, and it should go on the market next year.
Oculus shares more than doubled to $6.02 in premarket trading from Tuesday's close of $2.33.
The company conducted a study that showed the medication--meant to treat hypertrophic and keloid scarring from burns, general surgical procedures and trauma wounds--improved itching and pain relief in keloid scars.
OCLS drug was approved as a treatment for the pain and itch of scars after they have formed, not for the reduction of scarring. There are many such "treatments for scars" but there are no approved therapeutics for scar reduction, none.
rxi-109 is being developed for pre surgery as well as scar revision
good luck All
still holding. have added on latest dips. My feeling is that there seems to be lot of impatience hence the recent dips, then the dips spur further selling.
agree with you. fundamentals strong, on target on time and on cash.........good luck All
wild, as it was told to me by IR, all was supposedly set for the uplist but upon furhter review by nasdaq the uplist was made conditional. RXI must now trade above $4 to uplist.
What is bothersome is that you would think they would have postponed the reverse split until all conditions were finally met and signed off with nasdaq.
At this point I do not think there is anything company can do to expedite move to nasdaq. I am hopeful that we'll be trading higher in the near future..................good luck All
OK, thanks rhonda, but no thanks. This board is for messages. And the board sees to it.........................good luck All
don't ever be sorry for your thoughts grab. suggest you review my previous posts, then tell me if I am mistaken.....................good luck All
One more point grab, you take every opportunity to naysay this company, while claiming to be bullish. It is quite obvious to me, and possibly to others. a devil's advocate is one thing, but I am convinced that you subtly bash this company.........................good luck All
Just take a good look at the daily charts ( I am not a chartist ), to find that the frequency of trading, (by the mm's in my opinion) , as compared to today's pattern, is entirely different.
My point again, The company did inquire to the market as to the activity of rxi's market makers, and the trading pattern was abruptly changed.
What do you make of that?
My only point. And a valid one I believe..........good luck All
island, I hope you are correct. I still hold promise for their science, but the bigger problem now is how will the company stay afloat? No offense to the CEO, but I cannot help but think he is not capable of guiding this company.
I still follow, but will need a lot of convincing before I get back in. I should think many or most of their past followers share the sentiment..................good luck All
has made a marked difference in the trading pattern of the stock. Just to mention. Has anyone else noticed this ? .............................good luck All
bio, you may be on to something. I've noticed that this is the first day that I can remember that the daily chart has not shown the usual trading pattern. Perhaps the contact from the company raised some eyebrows...........hmmmm
stockwatcher, good post. CEO mentioned that the additional multi dose study will allow the Ph2 trials to be more finely tuned per dosing.
Keep in mind, the time span of these trials will be greatly expedited due to quick process of skin healing and that results are visible.
I do not feel that RXI has made any missteps in progressing rxi-109. Timely, on target, and on cash.
The only disappointment possibly timing of the stock split, but I believe that should resolve itself sooner than later (we hope).